PUT - SPRINTER OPEN END - BIOGEN IDEC | Real-time Boerse Frankfurt Warrants 10:43:41 2024-05-17 EDT | ||
| 13.84 EUR | +1.47% |
|
| Current month | -9.61% | ||
| 1 month | -19.72% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 13.84 | +1.47% |
| 24-05-16 | 13.64 | +4.44% |
| 24-05-15 | 13.06 | -7.57% |
| 24-05-14 | 14.13 | -0.56% |
| 24-05-13 | 14.21 | -1.32% |
Real-time Boerse Frankfurt Warrants
Last update May 17, 2024 at 10:43 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VQ8VDW |
| ISIN | DE000VQ8VDW1 |
| Date issued | 2021-06-22 |
| Strike | 375.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.12 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 18.12 € |
|---|---|
| Lowest since issue | 0.44 € |
| Spread | 0.03 € |
| Spread % | 0.22% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
230
USD
Average target price
285.9
USD
Spread / Average Target
+24.29%
- Stock Market
- Certificates
- Certificat
